Lexaria Bioscience Corp reports results for the quarter ended in May - Earnings Summary
12/07/2024 22:00
* Lexaria Bioscience Corp LEXX.OQ reported a quarterly
adjusted
loss of 13 cents per share for the quarter ended in May,
higher than the same quarter last year, when the company
reported EPS of -37 cents. The mean expectation of
three analysts for the quarter was for a loss of 10 cents per
share. Wall Street expected results to range from -13 cents
to -5 cents per share.
* Revenue fell 9.8% to $84.00 thousand from a year ago;
analysts
expected $150.00 thousand.
* Lexaria Bioscience Corp's reported EPS for the quarter was
a
loss of 13 cents.
* The company reported a quarterly loss of $1.78 million.
* Lexaria Bioscience Corp shares had risen by 1.1% this
quarter and gained 124.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 20.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Lexaria
Bioscience Corp is $10.00
This summary was machine generated from LSEG data July 12 at
09:00 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
May. 31 2024 -0.10 -0.13 Missed
Feb. 29 2024 -0.10 -0.06 Beat
Nov. 30 2023 -0.11 -0.13 Missed
Aug. 31 2023 -0.13 -0.12 Beat